|
1.
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics. CA Cancer J Clin. 60:277–300. 2010.
|
|
2.
|
Hotta K, Matsuo K, Ueoka H, Kiura K,
Tabata M and Tanimoto M: Meta-analysis of randomized clinical
trials comparing cisplatin to carboplatin in patients with advanced
non-small-cell lung cancer. J Clin Oncol. 22:3852–3859. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Ree SG, Kang SW, Chang TS, Jeong W and Kim
K: Peroxiredoxin, a novel family of peroxidases. IUBMB Life.
52:35–41. 2001. View Article : Google Scholar
|
|
4.
|
Yanagawa T, Ishikawa T, Ishii T, Tabuchi
K, Iwasa S, Bannai S, Omura K, Suzuki H and Yoshida H:
Peroxiredoxin I expression in human thyroid tumors. Cancer Lett.
145:127–132. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Yanagawa T, Iwasa S, Ishii T, Tabuchi K,
Yusa H, Onizawa K, Omura K, Harada H, Suzuki H and Yoshida H:
Peroxiredoxin I expression in oral cancer: a potential new tumor
marker. Cancer Lett. 156:27–35. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA
and Chae HZ: Overexpression of peroxiredoxin in human breast
cancer. Anticancer Res. 21:2085–2090. 2001.PubMed/NCBI
|
|
7.
|
Lehtonen ST, Svensk AM, Soini Y, Paakko P,
Hirvikoski P, Kang SW, Saily M and Kinnula VL: Peroxiredoxins, a
novel protein family in lung cancer. Int J Cancer. 111:514–521.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Kim HJ, Chae HZ, Kim YJ, Kim YH, Hwangs
TS, Park EM and Park YM: Preferential elevation of Prx I and Trx
expression in lung cancer cells following hypoxia and in human lung
cancer tissues. Cell Biol Toxicol. 19:285–298. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Chang JW, Lee SH, Jeong JY, Chae HZ, Kim
YC, Park ZY and Yoo YJ: Peroxiredoxin-I is an autoimmunogenic tumor
antigen in non-small cell lung cancer. FEBS Lett. 579:2873–2877.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Chen MF, Keng PC, Shau H, Wu CT, Hu YC,
Liao SK and Chen WC: Inhibition of lung tumor growth and
augmentation of radiosensitivity by decreasing peroxiredoxin I
expression. Int J Radiat Oncol Biol Phys. 64:581–591. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Kim YJ, Lee WS, IP C, Chae HZ, Park EM and
Park YM: Prx1 suppresses radiation-induced c-Jun NH2-terminal
kinase signaling in lung cancer cells through interaction with the
glutathione S-transferase Pi/c-Jun NH2-terminal kinase complex.
Cancer Res. 66:7136–7142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Gligorov J and Lotz JP: Preclinical
pharmacology of the taxanes: implications of the differences.
Oncologist. 9(Suppl 2): S3–S8. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Posner MR: Docetaxel in squamous cell
cancer of the head and neck. Anticancer Drugs. 12(Suppl 1):
S21–S24. 2001.
|
|
14.
|
Rowinsky EK: The development and clinical
utility of the taxane class of antimicrotubule chemotherapy agents.
Annu Rev Med. 48:353–374. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Shepherd FA, Dancey J, Ramlau R, Mattson
K, Gralla R, O’Rourke M, Levitan N, Gressot L, Vincent M, Burkes R,
Coughlin S, Kim Y and Berille J: Prospective randomized trial of
docetaxel versus best supportive care in patients with
non-small-cell lung cancer previously treated with platinum-based
chemotherapy. J Clin Oncol. 18:2095–2103. 2000.
|
|
16.
|
Jordan MA and Wilson L: Microtubules as a
target for anticancer drugs. Nat Rev Cancer. 4:253–265. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Bhalla KN: Microtubule-targeted anticancer
agents and apoptosis. Oncogene. 56:9075–9085. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Haldar S, Chintapalli J and Croce CM:
Taxol induces bcl-2 phosphorylation and death of prostate cancer
cells. Cancer Res. 56:1253–1255. 1996.PubMed/NCBI
|
|
19.
|
Haldar S, Basu A and Croce CM: Bcl2 is the
guardian of micro-tubule integrity. Cancer Res. 57:229–233.
1997.PubMed/NCBI
|
|
20.
|
Lee LF, Li G, Templeton DJ and Ting JP:
Paclitaxel (Taxol)-induced gene expression and cell death are both
mediated by the activation of c–Jun NH2-terminal kinase (JNK/SAPK).
J Biol Chem. 273:28253–28260. 1998.
|
|
21.
|
Amato SF, Swart JM, Berg M, Wanebo HJ,
Mehta SR and Chiles TC: Transient stimulation of the
c-Jun-NH2-terminal kinase/activator protein 1 pathway and
inhibition of extracellular signal-regulated kinase are early
effects in paclitaxel-mediated apoptosis in human B lymphoblasts.
Cancer Res. 58:241–247. 1998.
|
|
22.
|
Mhaidat NM, Wang Y, Kiejda KA, Zhang XD
and Hersey P: Docetaxel-induced apoptosis in melanoma cells is
dependent on activation of caspase-2. Mol Cancer Ther. 6:752–761.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Mhaidat NM, Zhang XD, Jiang CC and Hersey
P: Docetaxel-induced apoptosis of human melanoma is mediated by
activation of c-Jun NH2-terminal kinase and inhibited by the
mitogen-activated protein kinase extracellular signal-regulated
kinase 1/2 pathway. Clin Cancer Res. 13:1308–1314. 2007. View Article : Google Scholar
|
|
24.
|
MacKeigan JP, Taxman DJ, Hunter D, Earp HS
III, Graves LM and Ting JP: Inactivation of the antiapoptotic
phosphatidylinositol 3-kinase-Akt pathway by the combined treatment
of taxol and mitogen-activated protein kinase kinase inhibition.
Clin Cancer Res. 8:2091–2099. 2002.
|
|
25.
|
Hu L, Hofmann J, Lu Y, Mills GB and Jaffe
RB: Inhibition of phosphatidylinositol 3’-kinase increases efficacy
of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer
Res. 62:1087–1092. 2002.
|
|
26.
|
Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ,
Ando A, Miyoshi Y, Maeda E, Noguchi S and Kato K: Prediction of
docetaxel response in human breast cancer by gene expression
profiling. J Clin Oncol. 23:422–431. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Chhipa RR, Lee KS, Onate S, Wu Y and Ip C:
Prx1 enhances androgen receptor function in prostate cancer cells
by increasing receptor affinity to dihydrotestosterone. Mol Cancer
Res. 7:1543–1552. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Crissman HA and Steinkamp JA: Cell
cycle-related changes in chromatin structure detected by flow
cytometry using multiple DNA fluorochromes. Eur J Histochem.
37:129–138. 1993.PubMed/NCBI
|
|
29.
|
Lowry OH, Rosebrough NJ, Farr AL and
Randall RJ: Protein measurement with the Folin phenol reagent. J
Biol Chem. 193:265–275. 1951.PubMed/NCBI
|
|
30.
|
Dumontet C and Sikic BI: Mechanisms of
action of and resistance to antitubulin agents: microtubule
dynamics, drug transport and cell death. J Clin Oncol.
17:1061–1070. 1999.PubMed/NCBI
|
|
31.
|
Montegomery RB, Bonham M, Nelson PS, Grim
J, Makary E, Vessella R and Stahl WL: Estrogen effects on tubulin
expression and taxane mediated cytotoxicity in prostate cancer
cells. Prostate. 65:141–150. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Yu D, Jing T, Liu B, Yao J, Tan M,
McDonnell TJ and Hung MC: Overexpression of ErbB2 blocks
Taxol-induced apoptosis by upregulation of p21Cip1,
which inhibits p34Cdc2 kinase. Mol Cell. 2:581–591. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Wu JD, Haugk K, Coleman I, Woodke L,
Vessella R, Nelson P, Montgomery RB, Ludwig DL and Plymate SR:
Combined in vivo effect of A12, a type 1 insulin-like growth factor
receptor antibody and docetaxel against prostate cancer tumors.
Clin Cancer Res. 12:6153–6160. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Xing H, Weng D, Chen G, Tao W, Zhu T, Yang
X, Meng L, Wang S, Lu Y and Ma D: Activation of
fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by
regulating survivin protein expression in ovarian and breast cancer
cells. Cancer Lett. 261:108–119. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Kosaka T, Miyajima A, Shirotake S, Suzuki
E, Kikuchi E and Oya M: Long-term androgen ablation and docetaxel
up-regulate phosphorylated Akt in castration resistant prostate
cancer. J Urol. 185:2376–2381. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Brunet A, Sweeney LB, Sturgill JF, Chua
KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu
LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW and
Greenberg ME: Stress-dependent regulation of FOXO transcription
factors by the SIRT1 deacetylase. Science. 303:2011–2015. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Biggs WH III, Meisenhelder J, Hunter T,
Cavenee WK and Arden KC: Protein kinase B/Akt-mediated
phosphorylation promotes nuclear exclusion of the winged helix
transcription factor of FKHR1. Proc Natl Acad Sci USA.
96:7421–7426. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Kops GJ and Burgering BM: Forkhead
transcription factors: new insights into protein kinase B (c-akt)
signaling. J Mol Med. 77:656–665. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Nakae J, Park BC and Accili D: Insulin
stimulates phosphorylation of the forkhead transcription factor
FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol
Chem. 274:15982–15985. 1999. View Article : Google Scholar
|
|
40.
|
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo
P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt
promotes cell survival by phosphorylating and inhibiting a Forehead
transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Suhara T, Kim HS, Kirshenbaum LA and Walsh
K: Suppression of Akt signaling induces Fas ligand expression:
involvement of caspase and Jun kinase activation in Akt-mediated
Fas ligand regulation. Mol Cell Biol. 22:680–691. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Dijkers PF, Medema RH, Lammers JW,
Koenderman L and Coffer PJ: Expression of the pro-apoptotic Bcl-2
family member Bim is regulated by the forkhead transcription factor
FKHR-L1. Curr Biol. 10:1201–1204. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Modur V, Nagarajan R, Evers BM and
Milbrandt J: FOXO proteins regulate tumor necrosis factor-related
apoptosis inducing ligand expression. Implications for PTEN
mutation in prostate cancer. J Biol Chem. 277:47928–47937. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Kavurma MM and Khachigian LM: Signaling
and transcriptional control of Fas ligand gene expression. Cell
Death Differ. 10:36–44. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Lee YJ, Park MY and Kang YA: Enhancement
of sensitivity of human lung cancer cell line to TRAIL and
gefitinib of IGF-1R blockade. Tuberc Respir Dis. 63:42–51. 2007.
View Article : Google Scholar
|
|
46.
|
Greer EL and Brunet A: FOXO transcription
factors at the interface between longevity and tumor suppression.
Oncogene. 24:7410–7425. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Sunters A, Femandez de Mattos S, Stahl M,
Brosens JJ, Zoumpoulidou G, Saunders CA, Coffer PJ, Medema RH,
Coombes RC and Lam EW: FoxO3a transcriptional regulation of Bim
controls apoptosis in paclitaxel-treated breast cancer cell lines.
J Biol Chem. 278:49795–49805. 2003. View Article : Google Scholar : PubMed/NCBI
|
